Adaptimmune Therapeutics (FRA:473A) Total Long-Term Assets: €45.53 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:473A Adaptimmune Therapeutics PLC FRA:473A
16 GF Score
Price €0.16
View Full Analysis

What is Adaptimmune Therapeutics Total Long-Term Assets?

Adaptimmune Therapeutics FRA:473A 16 Total Long-Term Assets is €45.53 Mil as of Jun. 2025. GuruFocus rates FRA:473A with a GF Score™ of 16/100.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Adaptimmune Therapeutics's Total Long-Term Assets for the quarter that ended in Jun. 2025 was €45.53 Mil.

Adaptimmune Therapeutics Total Long-Term Assets Related Terms

Adaptimmune Therapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Total Long-Term Assets Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.56 47.87 69.43 68.83 55.19

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.11 65.97 55.19 50.94 45.53
FRA:473A
16GF Score
Adaptimmune Therapeutics PLC FRA:473A
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptimmune Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €45.53 Mil mean?
Adaptimmune Therapeutics (FRA:473A) has a Total Long-Term Assets of €45.53 Mil as of Jun. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Total Long-Term Assets too high?
Adaptimmune Therapeutics' current Total Long-Term Assets is €45.53 Mil. Overall, Adaptimmune Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adaptimmune Therapeutics' Total Long-Term Assets compare to BCLI and APRE?
Adaptimmune Therapeutics' Total Long-Term Assets of €45.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Total Long-Term Assets is €45.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (FRA:473A) has a current Total Long-Term Assets of €45.53 Mil. The current Total Long-Term Assets is €45.53 Mil. Adaptimmune Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Adaptimmune Therapeutics (FRA:473A), the current Total Long-Term Assets is €45.53 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges ADAPY:USA473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
16GF Score

Get the complete analysis for FRA:473A

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price